| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Aytu BioPharma, Inc.$2.25
+0.05 (+2.27%)
D 23Pipeline Score Overvalued Pharma · Commercial
Market Cap
22.54 M
EPS
-4.30
P/E Ratio
-0.49 $
Value Trade
63.02 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
12.41 M
R&D Expenses
-
Total Assets
111.69 M
Total Liabilities
111.69 M
Equity
35.14 M
D/E Ratio
12,345
-3.52 %
Week
-12.75 %
1 Month
-4.58 %
3 Month
14.66 %
6 Month
-98.04 %
5 Year
-100 %
All Time
Cash Data
Cash Position
26.71 M
Monthly Burn
1.35 M
Runway
18 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
19.02 K
52 Week Range
1.46 - 3.07
% held by Insiders
8.98 %
% held by Institutions
36.55 %
Enterprise Value
18.76 M
Total Shares
10.74 M
Short %
3.85 %
Float Shares
9.06 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aytu BioPharma, Inc.
301Total events
1Upcoming
84Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 1
Jan 29, 2027
T2Milestone Payment
Additional $3 million payment due within 45 days of first anniversary of commercial launch
Event history 300
Jun 17, 2026
◆Oral PresentationPresentation
Fireside Q&A at Planet MicroCap Las Vegas 2026 Investor Conference
Feb 3, 2026
◆Quarterly UpdateCorporate
Report fiscal 2026 second quarter operational and financial results
Jan 20, 2026
▲Product LaunchEXXUAPost-Market
Nationwide commercial launch of EXXUA
major depressive disordersource ↗
Jan 20, 2026
Jan 20, 2026
●Oral PresentationEXXUAPresentation
Investor Day presentations on EXXUA
major depressive disordersource ↗
Jan 15, 2026
◆R&D DayPresentation
Aytu BioPharma to participate in Lytham Partners 2026 Investor Healthcare Summit
Dec 15, 2025
▲Product LaunchEXXUAPost-Market
Initial commercial availability of EXXUA
major depressive disordersource ↗
Dec 2025
▲Product LaunchEXXUAPost-Market
EXXUA commercially launched in the United States
major depressive disordersource ↗
Jun 2025
▲Partnership / LicenseEXXUACorporate
Exclusive agreement to commercialize EXXUA in the United States
major depressive disordersource ↗
2024
▲Manufacturing MilestoneCMC / Inspection
Enhanced margin improvement in ADHD products expected beginning in calendar 2024
Jan 2024
◆PDUFA DateRegulatory Filing
Expected FDA approval of Cotempla XR-ODT site transfer PAS
attention deficit hyperactivity disorder (ADHD)source ↗
Drug Pipeline Intelligence
D23
Pipeline Score $9M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.4x
rNPV / MCap Top 22%
Micro Cap (rank 712 of 911)
Percentile RankAytu BioPharma, Inc. faces pipeline headwinds (23/100), with $464M risk-adjusted pipeline value, led by NT0102 in Attention Deficit Hyperactivity Disorder (ADHD) (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NT0102 Small molecule | Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | NCT01835548 | 49% | $464M | COMPLETED | 87 | - | - | Jul 1, 2014 | - | Jan 17, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Healight | Ventilator-Associated Pneumonia | Preclinical | 2022-04-25 | 46% reduction in multidrug-resistant Pseudomonas aeruginosa (PA C1-17) versus controls following two separate 20-minute treatments Read More | Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight Delivery Technology Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Read More | |
Healight | Ventilator-Associated Pneumonia | Preclinical | 2022-04-25 | 46% reduction in multidrug-resistant Pseudomonas aeruginosa (PA C1-17) versus controls following two separate 20-minute treatments Read More | Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight Delivery Technology Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Read More | |
Healight | Ventilator-Associated Pneumonia | Preclinical | 2022-04-25 | 46% reduction in multidrug-resistant Pseudomonas aeruginosa (PA C1-17) versus controls following two separate 20-minute treatments Read More | Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight Delivery Technology Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AYTU
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AYTU Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AYTUAytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
Aytu BioPharma will present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026. The company will participate in a Fireside Q&A session and conduct one-on-one investor meetings. This event highlights Aytu's commitment to engaging with investors and promoting its innovative medicines for CNS diseases.
Read more →AYTU▼ -10.3%on this news
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
Aytu BioPharma reported its fiscal 2026 second quarter results, highlighting a net revenue of $15.2 million and a net loss of $10.6 million. The company successfully launched EXXUA, a new treatment for major depressive disorder, in December 2025, with initial positive indicators from prescriber engagement. Despite challenges, including a decrease in revenue from other product portfolios, Aytu maintains a strong cash position to support its growth strategy.
Read more →AYTUAytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
Aytu BioPharma will report its operational and financial results for the second quarter of fiscal 2026 on February 3, 2026. The company has scheduled a conference call and webcast for the same day to discuss these results. Interested parties can access the call through provided dial-in information and a webcast link.
Read more →AYTUAytu BioPharma Recaps Investor Day Held on January 20, 2026
Aytu BioPharma held its Investor Day on January 20, 2026, focusing on the launch of EXXUA, the first FDA-approved 5HT1A agonist for major depressive disorder. Key opinion leaders and Aytu's management presented insights on the drug's clinical importance, commercialization strategy, and early positive feedback. The company plans to provide ongoing updates to investors.
Read more →AYTUAytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
Aytu BioPharma has launched EXXUA, the first selective 5-HT1A agonist approved for treating major depressive disorder in adults. This new treatment aims to reduce common side effects like sexual dysfunction and weight gain, which often lead to treatment discontinuation. The company emphasizes the importance of addressing both emotional and physical health in managing depression.
Read more →AYTUAytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
Aytu BioPharma will participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026. CEO Josh Disbrow will be part of a fireside chat moderated by Thomas Flaten from Lake Street Capital Markets. The event will be accessible via webcast, with a replay option available.
Read more →AYTU▲ +10.1%on this news
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results Q1 2024 Adjusted EBITDA of $2.2 million Rx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024 Q1 2024 ADHD net revenue u
Aytu BioPharma announced its financial results for the first quarter of fiscal 2024, highlighting an Adjusted EBITDA of $2.2 million and a net revenue of $22.1 million. Despite the overall revenue decline, the ADHD segment showed significant growth, with a revenue increase of 31% compared to the previous year. The company continues to focus on its Rx segment while planning to wind down the Consumer Health segment, which has seen a substantial drop in revenue. Aytu also reported a current cash balance of $20 million, positioning it for potential growth in the coming quarters.
Read more →AYTU▲ +5.8%on this news
Aytu BioPharma Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla
Aytu BioPharma has received FDA approval for its Prior Approval Supplement (PAS) to transfer manufacturing of Cotempla XR-ODT to a third-party contract manufacturer. This follows a similar approval for Adzenys XR-ODT earlier this year. The company anticipates that the move will not only reduce overhead costs but also lead to enhanced margins for its ADHD product offerings starting in 2024. Aytu is committed to ensuring a smooth transition to the new manufacturing site to meet growing prescription demands for both products.
Read more →AYTU▲ +16.4%on this news· ran to +76% by day 3
Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023 Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 millio
Aytu BioPharma reported its financial results for Q4 2023, achieving record net revenues of $30.7 million and an Adjusted EBITDA of $7.7 million. The Rx segment saw a notable increase in total prescriptions, growing by 32% year-over-year. Despite these successes, the company continues to face challenges, notably in its Consumer Health segment, which contributed negative Adjusted EBITDA. Moving forward, Aytu plans to focus on the Rx segment and monetize or discontinue its Consumer Health operations to enhance profitability.
Read more →AYTUAytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT and Cotempla XR-ODT in Israel and the Palestinian Authority After the completion of local regulatory approvals, Aytu a
Aytu BioPharma has entered into an exclusive agreement with Medomie Pharma Ltd. to distribute its ADHD medications, Adzenys XR-ODT and Cotempla XR-ODT, in Israel and the Palestinian Authority. The collaboration represents Aytu's first international commercial agreement for these products. Medomie will handle local regulatory approvals and aims to enhance ADHD treatment accessibility in the region.
Read more →AYTU▲ +5.4%on this news
Aytu BioPharma Announces Submission of Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement Company Expects a Six-Month Review of the Prior Approval Supplement Submission by the U.S. Food & Drug Administ
Aytu BioPharma has submitted a Prior Approval Supplement (PAS) to the FDA for the manufacturing site transfer of Cotempla XR-ODT. The company anticipates a six-month review process, which, if approved, will allow production to shift to a third-party manufacturer. This move is expected to enhance profitability for Aytu's ADHD products by improving margins by approximately 15%. The transition is expected to begin by late 2023 or early 2024.
Read more →AYTUAytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Cl
Aytu BioPharma has announced a $4 million public offering of its common stock, which is set to close on June 13, 2023. This financing is expected to support the company's strategic shift towards their commercial prescription business and extend the interest-only period on an existing loan until January 2025. Additionally, Abhinav Jain from Nantahala Capital Management will be joining the company's Board of Directors. The company is also suspending its pipeline programs to reduce expenses and maintain financial sustainability.
Read more →AYTUAytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results Total prescriptions increased 32% compared to Q3 2022 to highest level in Company history Company to host conference call today at 4:30pm ET ENGL
Aytu BioPharma reported financial results for the third quarter of fiscal year 2023, highlighting a notable 32% increase in total prescriptions compared to the same period last year. The company achieved record prescription levels, particularly in its pediatric product line, which saw an 81% revenue increase. However, overall net revenue declined from $24.2 million to $22.7 million, primarily due to challenges in the ADHD segment where net revenue dropped despite a rise in prescriptions. The management remains optimistic about future growth, especially as they adjust their consumer health strategy towards e-commerce sales.
Read more →AYTUAytu BioPharma Subleases a Portion of Its Manufacturing Facility ENGLEWOOD, CO /
Aytu BioPharma has signed an agreement to sublease a portion of its manufacturing facility to AMT Manufacturing Solutions. This sublease, covering over 30% of Aytu's FDA-approved facility, is aimed at improving cost efficiency and reducing operational expenses associated with the company's ADHD product lines. Aytu anticipates that this partnership will boost margins and streamline production processes. The sublease is expected to expand by the end of 2024 to encompass the entirety of the facility, allowing AMTMS to enhance its contract manufacturing services.
Read more →AYTUAytu BioPharma Announces Approval of Adzenys XR-ODT Manufacturing Site Transfer U.S. Food & Drug Administration Approval of Prior Approval Supplement Enables Transfer of Adzenys Production to Contract Manufacturer in 202
Aytu BioPharma has announced FDA approval for the manufacturing site transfer of Adzenys XR-ODT to a third-party manufacturer. This development is expected to increase the product's margins by approximately 15% once the transfer is completed. Additionally, the company has successfully finished a bioequivalence study for Cotempla XR-ODT, with plans to submit its site transfer to the FDA mid-year 2023. Approval of the Cotempla site transfer is anticipated by late 2023 or early 2024.
Read more →AYTUAytu BioPharma Reports Second Quarter of Fiscal Year 2023 Second Consecutive Quarter of Positive Adjusted EBITDA Quarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx Segment Company to Host Conference Call T
Aytu BioPharma reported its financial results for Q2 FY2023, marking the second consecutive quarter of positive Adjusted EBITDA. The company's net revenue was $26.3 million, a 14% increase from the same quarter last year, with significant growth in the Rx segment driven by pediatric products. However, there was a net loss of $(6.7) million, influenced by an impairment related to pipeline development. The company continues to focus on transitioning its business strategy towards profitability by suspending costly clinical development programs.
Read more →AYTUAytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results ENGLEWOOD, CO /
Aytu BioPharma has announced a delay in filing its Form 10-Q for the second quarter of fiscal year 2023, which ended on December 31, 2022. This delay is due to additional management review and assessment concerning the accounting for previously issued warrants. The company asserts that this matter will not affect its overall financial results, including assets or revenue. Aytu plans to reschedule its quarterly conference call and file the report as soon as possible.
Read more →AYTU▼ -6.5%on this news
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance ENGLEWOOD, CO /
Aytu BioPharma has successfully regained compliance with Nasdaq's minimum bid price requirement as of January 23, 2023. The company confirmed that its stock maintained a closing bid price of $1.00 or higher for ten consecutive business days. Aytu BioPharma is focused on providing pediatric-focused prescription drugs and consumer health solutions. This compliance is a crucial step for the company in maintaining its listing on the Nasdaq Stock Market.
Read more →AYTU▲ +7.3%on this news
Aytu BioPharma Announces 1-for-20 Reverse Stock Split ENGLEWOOD, CO /
Aytu BioPharma, Inc. announced a 1-for-20 reverse stock split effective January 6, 2023, in an effort to regain compliance with Nasdaq's minimum bid price requirement of $1.00. The split will automatically convert every 20 shares of outstanding common stock into one share, reducing the total from approximately 68.8 million to 3.4 million shares. This action follows approval from stockholders during a Special Meeting on October 5, 2022, and aims to comply with Nasdaq rules by May 22, 2023, to avoid potential delisting.
Read more →AYTUIN THE COURT OF CHANCERY OF THE STATE OF DELAWARE nd RAFAL APONOWICZ, derivatively on behalf of Aytu Biopharma, Inc. and individually on behalf of himself and all other similarly situated stockholders of Aytu Biopharma,
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE nd RAFAL APONOWICZ, derivatively on behalf of Aytu Biopharma, Inc. and individually on behalf of himself and all other similarly situated stockholders of Aytu Biopharma, Inc. , Plaintiff, v. GARY CANTRELL, JOSHUA DISBROW, CARL D
Read more →AYTUAytu BioPharma Announces Highest Weekly Adzenys XR-ODT Prescriptions Generated Since Inception of RxConnect Adzenys XR-ODT Total Prescription (TRx) Unit Growth Driven by a Combination of Continued Sales Force Execution,
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT Prescriptions Generated Since Inception of RxConnect Adzenys XR-ODT Total Prescription (TRx) Unit Growth Driven by a Combination of Continued Sales Force Execution, Leveraging of the Aytu RxConnect Patient Support Program, a
Read more →AYTUAytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule ENGLEWOOD, CO /
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule ENGLEWOOD, CO / November 22, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-foc
Read more →AYTU▲ +12.6%on this news
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso ENGLEWOOD, CO /
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso ENGLEWOOD, CO / November 16, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq: AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescri
Read more →AYTUAytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023 Record Quarterly Net Revenue of $27.7 Million Driven by 34% Growth in Rx Segment Positive Adjusted EBITDA
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023 Record Quarterly Net Revenue of $27.7 Million Driven by 34% Growth in Rx Segment Positive Adjusted EBITDA for the Quarter of $1.4 Million Leadership Changes Implem
Read more →AYTUAytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on
Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022 ENGLEWOOD, CO / November 7, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq: AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused pre
Read more →AYTU▲ +6.7%on this news
Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan Amendment of Secured Loan Agreement Extends Interest-Only Period to January 2024 Amendment Defers Ove
Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan Amendment of Secured Loan Agreement Extends Interest-Only Period to January 2024 Amendment Defers Over $3 Million in Principal Payments Beyond 2023 Note Matur
Read more →AYTUAytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs Following a corporate review, Aytu BioPharma is indefinitely suspending clinical devel
Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs Following a corporate review, Aytu BioPharma is indefinitely suspending clinical development and removing expenses related to AR101/enzastaurin,
Read more →AYTU▼ -5.2%on this news· ran to -15% by day 3
Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT in Response to Reported Generic Adderall XR Supply Disruptions Adzenys XR-ODT is FDA-Approved as Bioequivalent to Adderall XR Reported Su
Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT in Response to Reported Generic Adderall XR Supply Disruptions Adzenys XR-ODT is FDA-Approved as Bioequivalent to Adderall XR Reported Supply Disruptions of Adderall XR Generic Equivalents Have t
Read more →AYTUAytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue Record fourth quarter and fiscal year net revenue driven by strong growth in Prescription segment Positive Adjusted EBITDA within Prescription seg
Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Record fourth quarter and fiscal year net revenue driven by strong growth in Prescription segment Positive Adjusted EBITDA within Prescription segment Company to Host Conference Call Today at 4:30pm ET ENGLEWOO
Read more →AYTUAytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on
Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022 ENGLEWOOD, CO / September 20, 2022 / Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressin
Read more →AYTUAytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin This Fourth Patent for AR101/Enzastaurin Strengthens and Broadens the Intellectual Property Portfolio Surrounding the Treatment of Inherite
Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin This Fourth Patent for AR101/Enzastaurin Strengthens and Broadens the Intellectual Property Portfolio Surrounding the Treatment of Inherited Vascular Disorders Including Vascular Ehlers-Danlos Syndr
Read more →AYTUAytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin First Issued U.S. Patent Covers Methods of Treating a Broad Range of Inherited Aortic Aneurism and Related Conditions Including Vascular Ehlers-
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin First Issued U.S. Patent Covers Methods of Treating a Broad Range of Inherited Aortic Aneurism and Related Conditions Including Vascular Ehlers-Danlos Syndrome Multiple Patent Families Filed in Key Glob
Read more →AYTUAytu BioPharma Announces Closing of $10.0 Million Registered Public Offering ENGLEWOOD, CO / ACCESSWIRE /
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering ENGLEWOOD, CO / ACCESSWIRE / August 15, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today
Read more →AYTUAytu BioPharma Announces Launch of Public Offering ENGLEWOOD, CO
Aytu BioPharma Announces Launch of Public Offering CO, August 8, 2022 - Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public off
Read more →AYTUAytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome ENGLEWOOD, CO /
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome ENGLEWOOD, CO / July 20, 2022 / Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today a
Read more →AYTUAytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors ENGLEWOOD, CO /
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors ENGLEWOOD, CO / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment
Read more →AYTU▼ -5.9%on this news
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History Strategic Prio
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History Strategic Priorities Focused on Driving Revenue Growth, Increasing Fina
Read more →AYTUAytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight Delivery Technology Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight Delivery Technology Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated Pne
Read more →AYTU▼ -12.7%on this news· ran to -30% by day 3
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome ENGLEWOOD, CO /
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome ENGLEWOOD, CO / April 19, 2022 / Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, tod
Read more →AYTUAytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT ENGLEWOOD, CO /
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for ENGLEWOOD, CO / March 23, 2022 / Aytu BioPharma, Inc. (NASDAQ: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly issued US paten
Read more →AYTU▲ +5.7%on this news
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering ENGLEWOOD, CO
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering ENGLEWOOD, CO, March 2, 2022 - Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the placement to a healthcare-dedicated
Read more →AYTU▲ +5.7%on this news
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome ENGLEWOOD, CO
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome ENGLEWOOD, CO, March 2, 2022 - Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today annou
Read more →AYTUAytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results Quarterly Net Revenue Increased 53% Year-over-year to $23.1 Million PREVEnt Pivotal Study for AR101 in Vascular Eh
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results Quarterly Net Revenue Increased 53% Year-over-year to $23.1 Million PREVEnt Pivotal Study for AR101 in Vascular Ehlers-Danlos Syndrome On-track to Begin in Mid-2022 Initia
Read more →AYTU▲ +13.9%on this news
Aytu BioPharma Completes $15 Million Debt Refinancing Englewood, CO
Aytu BioPharma Completes $15 Million Debt Refinancing Englewood, CO, January 31, 2022 - Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that it has entered into an agreement with the Aven
Read more →AYTUAytu BioPharma Appoints Mark Oki as Chief Financial Officer ENGLEWOOD, CO /
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer ENGLEWOOD, CO / January 4, 2022 / Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Mark Oki will join Ayt
Read more →AYTUEx. 99.1 Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome Pivotal clinical trial will begin in first half of 2022 ENGLEWOOD, CO
Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome Pivotal clinical trial will begin in first half of 2022 ENGLEWOOD, CO / December 13, 2021 / Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharm
Read more →AYTUAytu BioPharma Reports First Quarter 2022 Financial Results Quarterly net revenue increased 62% to $21.9 million Ended quarter with approximately $40.6 million in cash, cash equivalents and restricted cash Fully integrat
Aytu BioPharma Reports First Quarter 2022 Financial Quarterly net revenue increased 62% to $21.9 million Ended quarter with approximately $40.6 million in cash, cash equivalents Fully integrated and expanding RxConnect patient support program and salesforce drove growth acros
Read more →AYTU▲ +5.1%on this news
Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results Quarterly net revenue increased 74% sequentially to $23.5M; 138% year-over-year to $65.6M Ended quarter with approximately $50M in cash, c
Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results Quarterly net revenue increased 74% sequentially to $23.5M; 138% year-over-year to $65.6M Ended quarter with approximately $50M in cash, cash equivalents and Planned pivotal study for AR101 in
Read more →AYTUAytu BioScience Announces Close of Merger with Neos Therapeutics - $100M revenue specialty pharmaceutical company on an accelerated path to profitability 1 - - Company name change to Aytu BioPharma, Inc. becomes effectiv
Aytu BioScience Announces Close of Merger with Neos Therapeutics - $100M revenue specialty pharmaceutical company on an accelerated path to profitability1 - - Company name change to Aytu BioPharma, Inc. becomes effective today - - Former Neos Therapeutics board members Beth P
Read more →AYTUINVESTOR PRESENTATION, DATED DECEMBER 15, 2020 Exhitbit 99.1 Aytu BioScience (NASDAQ: AYTU) Announced 12/10/20: Aytu BioScience to Acquire Neos Therapeutics, Inc. (NASDAQ: NEOS) a ytubio.com 1 AYTU's Assertive M&A Has Cr
Aytu BioScience (NASDAQ: AYTU) Announced 12/10/20: Aytu BioScience to Acquire Neos Therapeutics, Inc. (NASDAQ: NEOS) a ytubio.com 1 AYTU's Assertive M&A Has Created Platform to Drive Growth and Support Acquisitions 2 Unique opportunity to acquire assets as a consolidator in a ma
Read more →AYTUAytu BioScience Announces $10.0 Million Bought Deal Offering ENGLEWOOD, CO / ACCESSWIRE /
Aytu BioScience Announces $10.0 Million Bought Deal Offering ENGLEWOOD, CO / ACCESSWIRE / December 10, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced to
Read more →AYTUAytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue 1 Specialty Pharmaceutical Company - Merger accelerates transformation to profitability, with estimated annual
BioScience and Neos Therapeutics Announce Merger Agreement, Creating a Combined Revenue1 Specialty Pharmaceutical Company CO and GRAND PRAIRIE, TX / ACCESSWIRE / December 10, 2020 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercial
Read more →AYTUPART IV Page Report of Independent Registered Public Accounting Firm F‑2 Consolidated Balance Sheets at
Page Report of Independent Registered Public Accounting Firm F 2 Consolidated Balance Sheets at December 31, 2019 and 2018 F 3 Consolidated Statements of Operations for the years ended December 31, 2019, 2018 and 2017 F 4 Consolidated Statements of Comprehensive Loss for the yea
Read more →AYTUAytu BioScience (NASDAQ: AYTU) Aytu BioScience to Acquire Neos Therapeutics, Inc.
Aytu BioScience (NASDAQ: AYTU) Aytu BioScience to Acquire Neos Therapeutics, Inc. December 10, 2020 a ytubio.com 1 Transaction Highlights & Strategic Rationale x Transaction creates highly diversified specialty pharmaceutical company with $100mm of pro forma revenue Brand Market
Read more →AYTUAytu BioScience Announces Fiscal Q1 2021 Net Revenue of $13.5 Million, an Increase of 839% Year-Over-Year Q1 Consumer Health revenue reaches an all-time high of $7.8 million Live Conference Call and Webcast at 4:30 PM ES
Aytu BioScience Announces Fiscal Q1 2021 Net Revenue of $13.5 Million, an Increase of 839% Year-Over-Year Q1 Consumer Health revenue reaches an all-time high of $7.8 Live Conference Call and Webcast ENGLEWOOD, CO / ACCESSWIRE / November 12, 2020 / Aytu BioScience, Inc. (NAS
Read more →AYTUAytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year Company's highest revenue quarter to date is more than 2X its entire fiscal 2019 revenue ENG
BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Company's highest revenue quarter to date is more than 2X its entire fiscal 2019 revenue ENGLEWOOD, CO / ACCESSWIRE / October 6, 2020 / Aytu BioScience, Inc. (NASDAQ:
Read more →AYTUAytu BioScience Announces $15 Million Debt Retirement Company Retires $15M Obligation Assumed with Previously Announced Cerecor Commercial Portfolio Asset Purchase ENGLEWOOD, CO / ACCESSWIRE /
Announces $15 Million Debt Retirement Company Retires $15M Obligation Assumed with Previously Announced Cerecor Commercial Portfolio Asset Purchase ENGLEWOOD, CO / ACCESSWIRE / June 1, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Compan
Read more →AYTUAytu BioScience Reports Third Quarter Fiscal 2020 Financial Results Company Reports Revenue for the Three Months Ended
Aytu BioScience Reports Third Quarter Fiscal 2020 Financial Results Revenue for the Three Months Ended March 31, 2020 of $8.2M, Up 243% Cash and Cash Equivalents as of March 31, 2020 Management to Host Conference Call at 4:30 PM ENGLEWOOD, CO / ACCESSWIRE / May 14, 2020 / Ay
Read more →AYTUAytu BioScience to Report Fiscal Q3 FY 2020 Results and Business Update ENGLEWOOD, CO
Aytu BioScience to Report Fiscal Q3 FY 2020 Results and Business ENGLEWOOD, CO May 7, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced tod
Read more →AYTUAytu BioScience Announces China Export Clearance of Company's COVID-19 IgG/IgM Rapid Test 500,000 Rapid Tests Cleared for Shipment to Company's Warehouse ENGLEWOOD, CO / ACCESSWIRE /
Aytu BioScience Announces China Export Clearance of Company's COVID-19 IgG/IgM Rapid Test 500,000 Rapid Tests Cleared for Shipment to Company's CO / ACCESSWIRE / April 30, 2020 / Aytu BioScience, Inc. (NASDAQ: AYTU) (the Company ), a specialty pharmaceutical company focused
Read more →AYTUAytu BioScience Announces Results from Annual Stockholders Meeting Company's Board of Directors Elects Not to Effect a Reverse Stock Split ENGLEWOOD, CO / ACCESSWIRE /
Aytu BioScience Announces Results from Annual Stockholders Company's Board of Directors Elects Not to Effect a Reverse ENGLEWOOD, CO / ACCESSWIRE / April 24, 2020 / Aytu BioScience, Inc. (NASDAQ: AYTU) (the Company ), a specialty pharmaceutical company focused on commerciali
Read more →AYTUAytu BioScience Announces Exclusive Distribution Agreement for COVID-19 IgG/IgM Rapid Test with Singapore-Based Biolidics Limited ENGLEWOOD, CO / ACCESSWIRE /
Aytu BioScience Announces Exclusive Distribution Agreement for COVID-19 IgG/IgM Rapid Test with Singapore-Based Biolidics ENGLEWOOD, CO / ACCESSWIRE / April 23, 2020 / Aytu BioScience, Inc. (NASDAQ: AYTU) (the Company ), a specialty pharmaceutical company focused on commerci
Read more →AYTUAytu BioScience Signs Exclusive Global License with Cedars-Sinai for Potential Coronavirus Treatment Cedars-Sinai-Developed ‘Healight' Medical Device Platform Technology Being Studied as a Potential First-in-Class
Aytu BioScience Signs Exclusive Global License with Cedars-Sinai for Potential Coronavirus Cedars-Sinai-Developed Healight' Medical Device Platform Technology Being Studied as a Potential First-in-Class Conference Call Scheduled for Tuesday, April 21, 2020 at 4:30 pm CO / AC
Read more →AYTUAytu BioScience Confirms Export and Incoming Delivery of COVID-19 IgG/IgM Rapid Tests Chinese Officials Confirm China Won't Restrict Exports of Medical Products Needed to Fight Coronavirus Company in Late-Stage Negotiati
BioScience Confirms Export and Incoming Delivery of COVID-19 Chinese Officials Confirm China Won't Restrict Exports of Medical Products Needed to Fight Coronavirus Company in Late-Stage Negotiations to Secure Distribution Agreement for Additional COVID-19 IgG/IgM Rapid Test
Read more →AYTUAytu BioScience Announces Positive Results from an Independently Conducted Clinical Study of the Company's Licensed COVID-19 IgG/IgM Point-of-Care Rapid Test Independent clinical study demonstrates test accuracy of 98.0%
Aytu BioScience Announces Positive Results from an Independently Conducted Clinical Study of the Company's Licensed COVID-19 IgG/IgM Point-of-Care Rapid Test clinical study demonstrates test accuracy of 98.0% and 94.1% for IgG and IgM, respectively, when using PCR-positive ca
Read more →AYTUAytu BioScience Provides Update on its Licensed COVID-19 IgG/IgM Rapid Test Supply and Ongoing U.S. Distribution Company Places Third Purchase Order for One Million Tests ENGLEWOOD, CO / ACCESSWIRE /
Aytu BioScience Provides Update on its Licensed COVID-19 IgG/IgM Rapid Test Supply and Ongoing U.S. Distribution Company Places Third Purchase Order for One Million CO / ACCESSWIRE / April 15, 2020 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company foc
Read more →AYTUAytu BioScience Announces First Commercial Shipment of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test First COVID-19 Rapid Tests Delivered to Denver First Responders ENGLEWOOD, CO / ACCESSWIRE /
Aytu BioScience Announces First Commercial Shipment of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test First COVID-19 Rapid Tests Delivered to Denver First CO / ACCESSWIRE / April 3, 2020 / Aytu BioScience, Inc. (NASDAQ: AYTU), (the Company ), a specialty pharmaceut
Read more →AYTUAytu BioScience Announces Receipt of Initial Shipment of 100,000 COVID-19 IgG/IgM Point-of-Care Rapid Tests; Additional 500,000 Tests on Order Initial Shipment of 2-10 Minute COVID-19 Rapid Tests Received at Company's En
Aytu BioScience Announces Receipt of Initial Shipment of 100,000 COVID-19 IgG/IgM Point-of-Care Rapid Tests; Additional 500,000 Initial Shipment of 2-10 Minute COVID-19 Rapid Tests Received at Company's Englewood, Colorado Facility CO / ACCESSWIRE / April 1, 2020 / Aytu BioSc
Read more →AYTUAytu BioScience Submits Notice of Commercialization to the FDA, Allowing for Company's Distribution of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test Commercial Distribution of First 100,000 Tests to Commence
Aytu BioScience Submits Notice of Commercialization to the FDA, Allowing for Company's Distribution of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Commercial Distribution of First 100,000 Tests to Commence Upon Receipt of Inbound Product Shipment CO / ACCESSWIRE / March 2
Read more →AYTUAytu Announces $20.0 Million Registered Direct Offering Priced At-the-Market ENGLEWOOD, CO / ACCESSWIRE /
Aytu Announces $20.0 Million Registered Direct Offering Priced At-the-Market CO / ACCESSWIRE / March 12, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today annou
Read more →AYTUAytu Announces $9.0 Million Registered Direct Offering Priced At-the-Market ENGLEWOOD, CO / ACCESSWIRE /
Announces $9.0 Million Registered Direct Offering Priced At-the-Market CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced th
Read more →AYTUto this Current Report on Form 8-K/A are not specific to the identified assets acquired, and therefore the circumstances under which such impairment charges were recognized are not reflective of the Cerecor Transaction o
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS following unaudited pro forma condensed combined financial information is presented to illustrate the estimated effects of the unaudited pro forma condensed combined balance sheets at September 30, 2019 and the unaudit
Read more →AYTUAytu Reports Q2 Revenue of $3.2M, Up 77% Year-over-Year and 121% Sequentially ENGLEWOOD, CO / ACCESSWIRE /
Aytu Reports Q2 Revenue of $3.2M, Up 77% Year-over-Year and 121% ENGLEWOOD, CO / ACCESSWIRE / February 13, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing of novel products that address significant medical needs, today
Read more →AYTUAytu BioScience and Innovus Pharmaceuticals Announce Filing of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience ENGLEWOOD, CO & SAN DIEGO, CA / ACCESSWIRE /
Aytu BioScience and Innovus Pharmaceuticals Announce Filing of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience ENGLEWOOD, CO & SAN DIEGO, CA / ACCESSWIRE / December 24, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pha
Read more →AYTUproducts competing in the $40B consumer segment --> 0.05 --> $43M LTM revenue --> $19B TAM) -->
products competing in the $40B consumer segment --> 0.05 --> $43M LTM revenue --> $19B TAM) -->
Read more →AYTUAytu BioScience Announces Launch of Natesto® U.S. Co-Promotion with Acerus Pharmaceuticals Acerus Launches U.S. Specialty Sales Force; Sales Team Expansion Nearly Doubles Current Natesto Sales Force Expanded Commerc
Aytu BioScience Announces Launch of Natesto U.S. Co-Promotion with Acerus Pharmaceuticals Acerus Launches U.S. Specialty Sales Force; Sales Team Expansion Nearly Doubles Current Natesto Sales Force Expanded Commercial Operations Expected to Accelerate Natesto ENGLEWOOD, CO /
Read more →AYTUAytu Reports First Quarter 2020 Financial Results ENGLEWOOD, CO / ACCESSWIRE /
Aytu Reports First Quarter 2020 Financial Results ACCESSWIRE / November 14, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today will provide an overvi
Read more →AYTUAytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations ENGLEWOOD, CO / ACCESSWIRE /
Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations CO / ACCESSWIRE / November 11, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addre
Read more →AYTUAytu BioScience Announces Closing of $12.4M Prescription Product Portfolio Purchase Asset Purchase Increases Combined Company Annual Revenue to $44M, Including Previously Announced Acquisition of Innovus Pharmaceuticals
Aytu BioScience Announces Closing of $12.4M Prescription Product Increases Combined Company Annual Revenue to $44M, Including Previously Announced Acquisition of Innovus in Near-Term Cost Savings Expected Through Efficient Sales Force Integration and Removal of Redundant Oper
Read more →AYTUBlueprint Aytu BioScience Acquires $12.4 Million Prescription Product Portfolio Transaction increases annual revenue to $44M and is expected to accelerate time to breakeven, following recently announced acq
Aytu BioScience Acquires $12.4 Million Prescription Product Transaction increases annual revenue to $44M and is expected to accelerate time to breakeven, following recently announced acquisition of Innovus Pharmaceuticals Total upfront consideration equals 1.4x LTM revenue pl
Read more →AYTUAytu BioScience Announces $10 Million Private Placement Armistice Capital and Altium Capital jointly participated in financing ENGLEWOOD, CO / ACCESSWIRE /
Aytu BioScience Announces $10 Million Private Capital and Altium Capital jointly participated in ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addr
Read more →AYTUAytu BioScience Reports 100% Revenue Growth to $7.3 million in FY 2019 Results Do Not Include September 2019 Definitive Agreement to Acquire Innovus Pharmaceuticals: Combined LTM revenues of over $31M, Diversifies produc
Aytu BioScience Reports 100% Revenue Growth to $7.3 million in FY Results Do Not Include September 2019 Definitive Agreement to Acquire Innovus Pharmaceuticals: Combined LTM revenues of over $31M, Diversifies product line by 10x to over 30 ENGLEWOOD, CO / ACCESSWIRE / Septemb
Read more →AYTUFiled by Aytu BioScience, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Aytu BioScience, Inc. (SEC File No.
Filed by Aytu BioScience, Inc. Pursuant to Rule 425 under the Securities Act of and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Aytu BioScience, Inc. (SEC File No. 001-38247) Aytu BioScience Announces Definitive Agreement to Acquire Innovus
Read more →AYTUAytu BioScience Expands Natesto® Partnership with Acerus Pharmaceuticals to Accelerate Natesto Growth in the U.S. Acerus to Launch U.S. Specialty Sales Force; Nearly Doubles Natesto Sales Force ENGLEWOOD, CO / ACCES
Aytu BioScience Expands Natesto Partnership with Acerus Pharmaceuticals to Accelerate Natesto Growth in the Acerus to Launch U.S. Specialty Sales Force; Nearly Doubles Natesto ENGLEWOOD, CO / ACCESSWIRE / July 30, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharm
Read more →AYTUAytu BioScience Reports 291% Revenue Growth in Q3 FY19 Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE /
Aytu BioScience Reports 291% Revenue Growth in Q3 FY19 Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE / May 14, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address sig
Read more →AYTUAytu BioScience Announces Submission of ZolpiMist™ for Approval to Australian Therapeutic Goods Administration (TGA) Australian TGA Approval Decision Expected in Early 2020 ENGLEWOOD, CO / ACCESSWIRE /
Aytu BioScience Announces Submission of ZolpiMist for Approval to Australian Therapeutic Goods Administration Australian TGA Approval Decision Expected in Early ENGLEWOOD, CO / ACCESSWIRE / April 24, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical comp
Read more →AYTUAytu BioScience Reports 71% Revenue Growth in Q2 FY19 Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE /
Aytu BioScience Reports 71% Revenue Growth in Q2 FY19 Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE / February 7, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address
Read more →AYTUAytu BioScience Announces Positive Interim Results from Natesto Spermatogenesis Study Fertility Preserved in Hypogonadal Men Taking Natesto, Based on Semen Analyses Conducted at Three-Month and Six-Month Timepoints ENGLE
BioScience Announces Positive Interim Results from Natesto Spermatogenesis Study Preserved in Hypogonadal Men Taking Natesto, Based on Semen Analyses Conducted at Three-Month and Six-Month Timepoints CO / ACCESSWIRE / November 15, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a
Read more →AYTUAytu BioScience Reports 55% Sequential Revenue Growth in Q1 FY19; Adds Tuzistra XR to Portfolio Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE /
Aytu BioScience Reports 55% Sequential Revenue Growth in Q1 FY19; Adds Tuzistra XR to Portfolio Company Posts Highest Ever Quarterly Revenue ENGLEWOOD, CO / ACCESSWIRE / November 7, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on glo
Read more →AYTUAytu BioScience Enters $3 Billion Cough and Cold Market and Expands Primary Care Portfolio, with Exclusive U.S. Licensing of Revenue-Generating, FDA-Approved Antitussive Tuzistra XR Armistice Capital to Make $5M Strategi
Aytu BioScience Enters $3 Billion Cough and Cold Market and Expands Primary Care Portfolio, with Exclusive U.S. Licensing of Revenue-Generating, FDA-Approved Antitussive Armistice Capital to Make $5M Strategic Investment in Conjunction with Tuzistra XR Acquisition to Accelerat
Read more →AYTUAytu BioScience Announces Issuance of First U.S. Patent Covering MiOXSYS for Male Infertility; Company Progresses Toward U.S. Regulatory Clearance and Commercialization U.S. Patent Number 10,088,466 is Company's First Un
Announces Issuance of First U.S. Patent Covering MiOXSYS for Male Infertility; Company Progresses Toward U.S. Regulatory Clearance and Commercialization 10,088,466 is Company's First United States Patent Covering MiOXSYS for Male Inferility Assessment ENGLEWOOD, CO / ACCESSWIR
Read more →AYTUAytu BioScience Announces Publication of Manuscript Summarizing Results from the Ongoing Natesto Spermatogenesis Study Sperm Concentration, Motility, and Total Motile Sperm Count Remain Within Normal Ranges in Hypogonada
Aytu BioScience Announces Publication of Manuscript Summarizing Results from the Ongoing Natesto Spermatogenesis Study Sperm Concentration, Motility, and Total Motile Sperm Count Remain Within Normal Ranges in Hypogonadal Men Taking Natesto ENGLEWOOD, CO / ACCESSWIRE / Sept
Read more →AYTUNatesto Q4 Revenue Increases 178% Sequentially; Q4 Product Revenue Increases 52% Sequentially Highest Ever Quarterly Net Revenue for Natesto Testosterone Nasal Gel ENGLEWOOD, CO / ACCESSWIRE /
Natesto Q4 Revenue Increases 178% Sequentially; Q4 Product Revenue Increases 52% Sequentially Highest Ever Quarterly Net Revenue for Natesto Testosterone Nasal Gel ENGLEWOOD, CO / ACCESSWIRE / September 6, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutic
Read more →AYTUAytu BioScience to Report Fiscal Fourth Quarter 2018 Results and Business Update Live Conference Call and Webcast Scheduled for
BioScience to Report Fiscal Fourth Quarter 2018 Results and Business Update Live Conference Call and Webcast Scheduled for September 6, 2018, at 4:30 p.m. ET ENGLEWOOD, CO / ACCESSWIRE / August 30, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical compan
Read more →AYTUAytu BioScience Enters $1.8 Billion U.S. Prescription Sleep Aid Market with Exclusive License to Zolpimist to Expand Company's Commercial-Stage Product Portfolio Company acquires FDA-approved, commercial-stage product to
Aytu BioScience Enters $1.8 Billion U.S. Prescription Sleep Aid Market with Exclusive License to Zolpimist to Expand Company's Commercial-Stage Product Portfolio Company acquires FDA-approved, commercial-stage product to complement Natesto sales efforts among primary care phys
Read more →AYTUAytu BioScience Provides Fiscal Third Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm
BioScience Provides Fiscal Third Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET CO, May 14, 2018 /ACCESSWIRE/ -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in
Read more →AYTUDear Aytu BioScience Shareholders and Colleagues: In response to multiple inquiries from interested stakeholders, I'm pleased to provide a short, high-level summary of the Company's progress as we continue launching Nate
Dear Aytu BioScience Shareholders and Colleagues: In response to multiple inquiries from interested stakeholders, I'm pleased to provide a short, high-level summary of the Company's progress as we continue launching Natesto in the U.S., while building our commercial capabiliti
Read more →AYTUAytu BioScience Announces Closing of $12,000,000 Public Offering
Aytu BioScience Announces Closing of $12,000,000 ENGLEWOOD, Colo., March 6, 2018 - Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the closing
Read more →AYTUAytu BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET Natesto prescriptions increased 23% over previous quarter, and 317% over the same quarter last ye
BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET prescriptions increased 23% over previous quarter, and 317% over the same quarter last year Colo., Feb. 8, 2018 /PRNewswire/ -- Aytu BioScience, Inc. (NASDAQ: A
Read more →AYTUAytu BioScience Shareholders and Colleagues,
Aytu BioScience Shareholders and Colleagues, wanted to share some news with you to start 2018 in light of recent developments involving the U.S. testosterone replacement (TRT) market and in response to inquiries from various shareholders and other external stakeholders. There w
Read more →AYTUAytu BioScience Announces Appointment of David Green as Chief Financial Officer Englewood, CO
Aytu BioScience Announces Appointment of David Green as Chief Financial Officer Englewood, CO - December 18, 2017 - Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ann
Read more →AYTUAytu BioScience Provides Update on the Continued Growth of Natesto in the U.S. Englewood, CO
BioScience Provides Update on the Continued Growth of Natesto in the U.S. CO - November 28, 2017 - Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an update on
Read more →AYTUAytu BioScience Provides Fiscal First Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET Englewood, CO
BioScience Provides Fiscal First Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET CO - November 9, 2017 - Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the fiel
Read more →AYTUAytu BioScience, Inc. Proforma Balance Sheet
Aytu BioScience, Inc. Proforma Balance Sheet June 30, 2017 Unaudited 6/30/2017 Pro Forma Pro Forma Consolidated Adjustments (a) Combined (b) Assets Current assets Cash and cash equivalents $ 802,328 $ 10,637,752 $ 11,440,080 Restricted cash
Read more →AYTUAytu BioScience Provides Fiscal Fourth Quarter and Year-End 2017 Business Update Live Conference Call and Webcast Today at 10:30 a.m. ET Englewood, CO
Aytu BioScience Provides Fiscal Fourth Quarter and Year-End 2017 Business Update Live Conference Call and Webcast Today at 10:30 a.m. ET Englewood, CO - August 31, 2017 - Aytu BioScience, Inc. (OTCQX: AYTUD), a specialty life sciences company focused on global commercializati
Read more →AYTUAytu BioScience, Inc. Announces $11.5 Million Private Placement ENGLEWOOD, CO
Aytu BioScience, Inc. Announces $11.5 Million Private Placement ENGLEWOOD, CO, August 11, 2017 - Aytu BioScience, Inc. (OTCQX: AYTU) a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it has r
Read more →AYTUAytu BioScience Provides Third Quarter Fiscal 2017 Business Update
Aytu BioScience Provides Third Quarter Fiscal 2017 Live Conference Call and Webcast TODAY at 4:30 p.m. ET ENGLEWOOD, Colo., May 11, 2017 - Aytu BioScience, Inc. (OTCQX: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field
Read more →AYTUAytu BioScience Announces the Acquisition of Nuelle, Inc., Developer and Marketer of Fiera Female Personal Care Device Englewood, CO
Aytu BioScience Announces the Acquisition of Nuelle, Inc., Developer and Marketer of Fiera Female Personal Care Device Englewood, CO - May 9, 2017 - Aytu BioScience, Inc. (OTCQX: AYTU), a specialty life sciences company focused on global commercialization of novel products in
Read more →AYTUAytu BioScience Announces Divestiture of Primsol to Allegis Holdings Sale Price of $1.75 Million in Cash Further Supports Ongoing Commercialization of Natesto Englewood, CO
Aytu BioScience Announces Divestiture of Primsol to Allegis Holdings Sale Price of $1.75 Million in Cash Further Supports Ongoing Commercialization of Natesto Englewood, CO - April 3, 2017 - Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on g
Read more →AYTUAytu BioSciences Completes Successful Warrant Tender Offer and Receives $2.2 Million from Exercise of Warrants Englewood, CO
Aytu BioSciences Completes Successful Warrant Tender Offer and Receives $2.2 Million from Exercise of Warrants Englewood, CO - March 1, 2017 - Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the
Read more →AYTUAytu BioScience Provides Second Quarter Fiscal 2017 Business Update and Financial Results Product Revenues Increased 77% from Same Quarter in Prior Year; Cash Burn Reduced by 47% from Previous Quarter Forecasting Cash Fl
Aytu BioScience Provides Second Quarter Fiscal 2017 Business Update and Financial Results Product Revenues Increased 77% from Same Quarter in Prior Year; Cash Burn Reduced by 47% from Previous Quarter Forecasting Cash Flow Breakeven in ~18 Live Conference Call and Webcast TO
Read more →AYTUAytu BioScience Provides First Fiscal Quarter 2017 Business Update Live Conference Call and Webcast TODAY at 4:30 p.m. ET Englewood, CO
Aytu BioScience Provides First Fiscal Quarter 2017 Business Update Live Conference Call and Webcast TODAY Englewood, CO - November 07, 2016 - Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the f
Read more →AYTUAytu BioScience Announces Pricing of $8.6 Million Public Offering of Common Stock and Warrants Englewood, CO
Announces Pricing of $8.6 Million of Common Stock and Warrants Englewood, CO - October 27, 2016 - Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it has
Read more →AYTUAytu BioScience Provides Fiscal Fourth Quarter and Fiscal Year 2016 Business Update Live Conference Call and Webcast Today at 4:30 p.m.
Aytu BioScience Provides Fiscal Fourth Quarter and Fiscal Year 2016 Business Update Live Conference Call and Webcast Today at 4:30 p.m. ET ENGLEWOOD, Colo., Sept. 1, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global
Read more →AYTUAytu BioScience, Inc. Announces Common Stock Purchase Agreement for up to $10.5 Million Equity Commitment Supports the U.S. Launch of Natesto and the Company's Commercial Expansion
Aytu BioScience, Inc. Announces Common Stock Purchase Agreement for up to $10.5 Million Commitment Supports the U.S. Launch of Natesto and the Company's Commercial Expansion ENGLEWOOD, Colo., July 27, 2016- Aytu BioScience, Inc. (OTCQX: AYTU) ("Aytu"), a specialty pharmaceut
Read more →AYTUAytu BioScience Strengthens Board with the Appointment of Two Pharmaceutical Industry Veterans as Independent Directors Englewood, CO
Aytu BioScience Strengthens Board with the Appointment of Two Pharmaceutical Industry Veterans as Independent Directors Englewood, CO - July 13, 2016 - Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products
Read more →AYTUAytu BioScience to Optimize Capitalization in Support of Future Anticipated Uplisting of its Common Stock to a National Exchange Shareholders Authorize Board of Directors to Effect a Reverse Split of the Company's Common
Aytu BioScience to Optimize Capitalization in Support of Future Anticipated Uplisting of its Common Stock to a National Exchange Shareholders Authorize Board of Directors to Effect a Reverse Split of the Company's Common Stock Englewood, CO - May 25, 2016 - Aytu BioScience,
Read more →AYTUAytu BioScience Provides Third Fiscal Quarter 2016 Business Update Live Conference Call and Webcast TODAY at 4:30 p.m. ET Englewood, CO
Aytu BioScience Provides Third Fiscal Quarter 2016 Business Update Live Conference Call and Webcast TODAY Englewood, CO - May 11, 2016 - Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field
Read more →AYTUAytu BioScience Announces Closing of Public Offering Englewood, CO
Announces Closing of Public Offering Englewood, CO - May 6, 2016 - Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced the closing of its previously announced underwritten pu
Read more →AYTUAytu BioScience Announces Pricing of $7.5 Million Public Offering of Common Stock and Warrants Englewood, CO
Announces Pricing of $7.5 Million of Common Stock and Warrants Englewood, CO - May 2, 2016 - Aytu BioScience, Inc. ("Aytu") (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced that it has priced
Read more →AYTUAytu BioScience Enters $2 Billion Testosterone Replacement Market with Acquisition of U.S. Commercial Rights to Natesto Secures Long-term, Exclusive License from Acerus Pharmaceuticals Corporation Licenses Novel, FDA-App
Aytu BioScience Enters $2 Billion Testosterone Replacement Market with Acquisition of U.S. Commercial Rights to Natesto Secures Long-term, Exclusive License from Acerus Pharmaceuticals Corporation Licenses Novel, FDA-Approved Nasal Gel Testosterone Product; Planned for July
Read more →AYTUAytu BioScience Strengthens Board with Appointment of First Independent Director Veteran Financial Executive Carl Dockery Joins Aytu Englewood, CO
Aytu BioScience Strengthens Board with Appointment of First Independent Director Veteran Financial Executive Carl Dockery Englewood, CO - April 13, 2016 - Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on urological and related con
Read more →AYTUAytu BioScience Awarded Health Canada Approval for Its MiOXSYS System for Male Infertility Englewood, CO
Aytu BioScience Awarded Health Canada Approval for Its MiOXSYS System for Male Infertility Englewood, CO - March 31, 2016 - Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on global commercialization of novel products in the field
Read more →AYTUAytu BioScience Provides Second Fiscal Quarter Business Update Live Conference Call and Webcast TODAY at 4:30 p.m. ET Englewood, CO
Aytu BioScience Provides Second Fiscal Quarter Live Conference Call and Webcast TODAY at Englewood, CO - February 16, 2016 - Aytu BioScience, Inc. (OTCQX: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, provided to
Read more →AYTUAytu BioScience Announces Additions to Board of Directors Englewood, CO
Aytu BioScience Announces Additions to Englewood, CO - January 27, 2016 - Aytu BioScience, Inc. (OTCQX: AYTU), a specialty healthcare company focused on commercializing treatments for urological and related conditions, today announced that Josh Disbrow, Aytu's Chief Executive
Read more →AYTUAytu BioScience Acquires Second Revenue-Generating Urology Product Company to Begin Marketing Primsol Solution for Urinary Tract Infections Englewood, CO
Aytu BioScience Acquires Second Revenue-Generating Urology Product Company to Begin Marketing Primsol Solution for Urinary Tract Infections Englewood, CO October 6, 2015 Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for ur
Read more →AYTUAytu BioScience Provides First Quarterly Business Update Live Conference Call and Webcast Today at 4:30 p.m. ET Englewood, CO
Aytu BioScience Provides First Quarterly Business Update Live Conference Call and Webcast Today at 4:30 p.m. ET Englewood, CO September 28, 2015 Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related cond
Read more →AYTUAytu BioScience Completes $5.175 Million Private Placement Englewood, CO
Aytu BioScience Completes $5.175 Million Private Placement Englewood, CO September 2, 2015 Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that it has closed the final tr
Read more →AYTUREPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Vyrix Pharmaceuticals, Inc. and Luoxis Diagnostics, Inc. Greenwood Village, Colorado We have audited the accompanying
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Pharmaceuticals, Inc. and Luoxis Diagnostics, Inc. Greenwood Village, Colorado We have audited the accompanying combined balance sheets of Vyrix Pharmaceuticals, Inc. and Luo
Read more →Competitive Position
How AYTU ranks across every disease it competes inCompetitive Position is a premium feature
See how AYTU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial